This study is not yet accepting patients
REVERSE-Long COVID-19 With Baricitinib Pilot Study
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Priscilla Hsue, MD
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Priscilla Hsue, MD
Professional Experience: Dr. Hsue trained in Internal Medicine in the Molecular Medicine Training Program at UC San Francisco and in Cardiovascular Medicine at UC San Francisco. She served as Chief Cardiology Fellow during this time. She has been on the faculty in the Department of Medicine at San Francisco General Hospital since 2002.
Details
- Status
- not yet accepting patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Vanderbilt University Medical Center
- ID
- NCT05858515
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 30 study participants
- Last Updated